coroanrvisu_cdc’s weekly COVID-19 news round-up

pharmafile | May 6, 2020 | News story | Research and Development COVID-19, coronavirus 

Vaccines and treatments for COVID-19 continue to dominate the news, as two studies reveal “positive” data for Gilead’s remdesivir in hospitalised coronavirus patients while Lonza and Moderna have entered an agreement to mass produce a vaccine.

In other news, scientists expect the global pandemic to last as long as two years and believe it will not be properly under control until two-thirds of the world are immunised.

1. Arizona GOP lawmakers and AAPS say hydroxychloroquine has 90% chance of helping COVID-19 patients, but data is not based on clinical trialsPublished 29/04/2020

The Association of American Physicians and Surgeons (AAPS) wrote a letter to Republican Arizona Governor Doug Ducey urging the wider use of hydroxychloroquine, based on data they have collected.

2. Two studies reveal “positive” data for Gilead’s remdesivir in hospitalised COVID-19 patientsPublished 30/04/3030

The first findings of two new studies have been revealed, detailing the efficacy of Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with COVID-19.

3. Lonza and Moderna enter agreement to mass produce coronavirus vaccinePublished 04/05/2020

Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year.

4. COVID-19 pandemic likely to last two years, study saysPublished 01/05/2020

The coronavirus pandemic is likely to last as long as two years and will not be properly controlled until two-thirds of the world’s populations have become immune.

5. AstraZeneca joins forces with University of Oxford to develop and manufacture potential coronavirus vaccinePublished on 30/04/2020

A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with the former agreeing to aid in the development and large-scale manufacture of the latter’s potential recombinant adenovirus vaccine for the prevention of novel coronavirus infection.

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials …


Moderna files for FDA authorisation for updated COVID-19 vaccine

Biotechnology company Moderna has announced that it has completed submission of a regulatory application to …

Latest content